GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative – Hagens Berman

GeneDx Holdings stock plummeted 49% on May 5, 2025, after the company reported a massive Q1 2026 earnings miss, a tenfold increase in net loss, and significantly reduced full-year guidance. The company's average reimbursement rate fell short of expectations due to an adverse shift in product mix toward lower-margin genome tests. Hagens Berman has opened an investigation into potential securities law violations regarding whether management misled investors about product mix changes and growth projections.